SCHEMBL5538596

SCHEMBL5538596

CCC1CCCCC1(C(N)=O)c1ccccc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
HPGD P15428 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 2/20 0.38
SIGMAR1 Q99720 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
APP P05067 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6926708 0.99 LMNA (0.40) LMNAHPGDALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL6470509 0.86 SLC6A9 (0.37)
SCHEMBL518232 0.84 HDAC4 (0.43) LMNAALDH1A1L3MBTL1KMT2AHTT
SCHEMBL6472112 0.80 HDAC4 (0.45) ALDH1A1SMN1; SMN2KMT2APDE4D
SCHEMBL4566291 0.79 HPGD (0.41) LMNAHPGDALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL4984839 0.78 CHRM2 (0.49) ALDH1A1TSHRKMT2AHTTSIGMAR1
SCHEMBL6923376 0.78 SLC6A4 (0.43) LMNAALDH1A1L3MBTL1SMN1; SMN2KMT2A
SCHEMBL2120953 0.75 TRPA1 (0.43) LMNAALDH1A1SMN1; SMN2KMT2A
SCHEMBL6922910 0.74 HSD11B1 (0.40) LMNAALDH1A1KMT2AHTT
SCHEMBL4590444 0.74 SIGMAR1 (0.42) LMNASMN1; SMN2KMT2ASIGMAR1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 LMNA 2932/4885HPGD 3176/4885ALDH1A1 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.